Verastem, Inc. VSTM
7.41 USD -0.29 (-3.77%)
Regular-session close
7.35 -0.06 -0.81%
Pre-market · Nov 18, 8:18 AM ET
7.36 Day range 7.89
3.43 52-week range 10.82
- YTD
- -4.02%
- 1 year
- -19.02%
News
marketbeat.com Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance Verastem NASDAQ: VSTM is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a…
marketbeat.com Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path Verastem NASDAQ: VSTM plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile…benzinga.com RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $18 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $19 to $18.
benzinga.com HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $20 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $20.
benzinga.com Verastem Oncology Q3 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Verastem Oncology Files $100M At-The-Market Equity Offering Agreement With Cantor Fitzgerald This registration statement contains the following documents:• a base prospectus, which covers the offering, issuance and sale by us of an indeterminate amount of the securities identified below from…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.benzinga.com Verastem Q3 Adj. EPS $(0.72) Misses $(0.46) Estimate, Sales $24.012M Miss $26.078M Estimate Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.46) by 56.52 percent. This is a 33.33 percent decrease over losses of $(0.54)…
